Modest Association Between C-reactive Protein, Breast Cancer Risk

Share this content:

the Cancer Therapy Advisor take:

Higher levels of C-reactive protein (CRP), a nonspecific marker of inflammation, were suggestive of an association with increased breast cancer risk, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

In this study, 943 cases from the Nurses’ Health Study (NHS) and 1,919 cases from the Women’s Health Study (WHS) were evaluated.

Results showed higher CRP levels were associated with a greater risk of breast cancer for those in the NHS (quintile 5 vs. 1: RR, 1.27; 95% CI: 0.93, 1.73; P trend = 0.02). However, no correlation between CRP levels and breast cancer risk were observed in the WHS (quintile 5 vs. 1: RR, 0.89; 95% CI: 0.76, 1.06; P trend = 0.38).

The random effect meta-analysis conducted on the data showed a slightly increased risk in women with the highest versus lowest levels of CRP (RR, 1.26; 95% CI: 1.07, 1.49).

TKIs for chronic lymphocytic leukemia require not only long-term with oral medications but also prog
Higher levels of C-reactive protein were suggestive of an association with increased breast cancer risk.
Corresponding Author: Jun Wang, Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, 715 North Pleasant Street, Amherst, MA 01003. Phone: 413-545-0845; Fax: 413-545-1645; E-mail: junw{at} Background: C-reactive protein (CRP) has been evaluated as a risk factor for breast cancer in epidemiologic studies.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs